Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
What each said, in their own words
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
PGEU welcomes the opportunity to provide input in the context of the European Commission roadmap/inception impact assessment on the Evaluation and revision of the general pharmaceutical legislation. Our contribution addresses the issues that have a direct impact on community pharmacy, namely security of supply of medicines including shortages, medicines accessibility, and environmental sustainability.
European community pharmacists support the European Commission's proposal for the reform of the EU pharmaceutical legislation. PGEU believes the proposal includes important provisions to improve the supply of medicines to meet patients needs, regardless of where they live in the Union.
Unicancer, the French hospital federation of comprehensive cancer centers, expresses its gratitude to the European Commission for the opportunity to provide feedback in the public consultation on the legislative proposal for revising the EUs legislation on pharmaceuticals. While we welcome the proposal, we have five specific comments which we have integrated in the attached contribution: 1.
Out of the 180 HealthDCAT-AP properties reviewed in the Detailed Review sheet, 34 are recommended for inclusion in the minimum metadata set for data owners.The position is structured around six guiding principles : 1. Prefer controlled vocabularies over free text.
PGEU welcomes the aim of this draft Implementing Regulation to make dataset catalogues for secondary use standardised and interoperable. High-quality metadata can support public-interest research, public health, pharmacovigilance and evidence on medicines use. However, the catalogue must be a transparency tool, not a gateway to commercial exploitation of sensitive health data.
Take this comparison with you
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.